Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Three-Cohort, Phase 2 Study of E7080 (Lenvatinib) in Subjects With Recurrent Malignant Glioma

NCT01137604 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01137604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01137604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Three-Cohort, Phase 2 Study of E7080 (Lenvatinib) in Subjects With Recurrent Malignant Glioma
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 9, 2010
Completion date
October 28, 2014
Enrollment
151 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

glioma